Chemical modification of siRNAs for in vivo use

Oligonucleotides

Volumn 18, Issue 4, 2008, Pages 305-319

  Behlke, Mark A ^a  

^a INTEGRATED DNA TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 211745; ALN RSV01; ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVASIRANIB; CALAA 01; FORMIVIRSEN; IMATINIB; MICRORNA; NANOPARTICLE; NUCLEASE; PF 04523655; RANIBIZUMAB; RRM2; SINGLE STRANDED DNA; SMALL INTERFERING RNA; TD 101; TD101; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SCREENING; ENZYME STABILITY; FOOT DISEASE; GENETIC SUSCEPTIBILITY; HUMAN; IN VIVO STUDY; INCIDENCE; INNATE IMMUNITY; KIDNEY INJURY; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; RNA STRUCTURE; SOLID TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; MACULAR DEGENERATION; NEOPLASMS; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 57349134691     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0164     Document Type: Review

References (154)

1. ALEXOPOULOU, L., HOLT, A.C., MEDZHITOV, R., and FLAVELL, R.A. (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732-738.
2. ALLERSON, C.R., SIOUFI, N., JARRES, R., PRAKASH, T.P., NAIK, N., BERDEJA, A., WANDERS, L., GRIFFEY, R.H., SWAYZE, E.E., and BHAT, B. (2005). Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901-904.
3. AMARZGUIOUI, M., HOLEN, T., BABAIE, E., and PRYDZ, H. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595.
4. ANDERSON, E.M., BIRMINGHAM, A., BASKERVILLE, S., REYNOLDS, A., MAKSIMOVA, E., LEAKE, D., FEDOROV, Y., KARPILOW, J., and KHVOROVA, A. (2008). Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 14, 853-861.
5. ARMANT, M.A., and FENTON, M.J. (2002). Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. 3, REVIEWS3011.
6. BAGGA, S., BRACHT, J., HUNTER, S., MASSIRER, K., HOLTZ, J., EACHUS, R., and PASQUINELLI, A.E. (2005). Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122, 553-563.
7. BARTLETT, D.W., and DAVIS, M.E. (2007). Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 97, 909-921.
8. BARTLETT, D.W., and DAVIS, M.E. (2008). Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975-985.
9. BARTLETT, D.W., SU, H., HILDEBRANDT, I.J., WEBER, W.A., and DAVIS, M.E. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 104, 15549-15554.
10. BEHLKE, M.A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670.
11. BIRMINGHAM, A., ANDERSON, E.M., REYNOLDS, A., ILSLEYTYREE, D., LEAKE, D., FEDOROV, Y., BASKERVILLE, S., MAKSIMOVA, E., ROBINSON, K., KARPILOW, J., MARSHALL, W.S., and KHVOROVA, A. (2006). 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-204.
12. BRAASCH, D.A., JENSEN, S., LIU, Y., KAUR, K., ARAR, K., WHITE, M.A., and COREY, D.R. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42, 7967-7975.
13. BRAASCH, D.A., PAROO, Z., CONSTANTINESCU, A., REN, G., OZ, O.K., MASON, R.P., and COREY, D.R. (2004). Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14, 1139-1143.
14. BRAMSEN, J.B., LAURSEN, M.B., DAMGAARD, C.K., LENA, S.W., BABU, B.R., WENGEL, J., and KJEMS, J. (2007). Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 35, 5886-5897.
15. CHEN, D., TEXADA, D.E., DUGGAN, C., LIANG, C., REDEN, T.B., KOORAGAYALA, L.M., and LANGFORD, M.P. (2005). Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells. J. Biol. Chem. 280, 22425-22436.
16. CHEN, P.Y., WEINMANN, L., GAIDATZIS, D., PEI, Y., ZAVOLAN, M., TUSCHL, T., and MEISTER, G. (2008). Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14, 263-274.
17. CHIU, Y.L., and RANA, T.M. (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048.
18. CHOUNG, S., KIM, Y.J., KIM, S., PARK, H.O., and CHOI, Y.C. (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919-927.
19. CLARK, P.R., POBER, J.S., and KLUGER, M.S. (2008). Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect. Nucleic Acids Res. 36, 1081-1097.
20. COLLINGWOOD, M.A., ROSE, S.D., HUANG, L., HILLIER, C., AMARZGUIOUI, M., WIIGER, M.T., SOIFER, H.S., ROSSI, J.J., and BEHLKE, M.A. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18, 187-200.
21. CROOKE, S.T. (2004). Progress in antisense technology. Annu Rev Med 55, 61-95.
22. CZAUDERNA, F., FECHTNER, M., DAMES, S., AYGUN, H., KLIPPEL, A., PRONK, G.J., GIESE, K., and KAUFMANN, J. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716.
23. DAHLGREN, C., ZHANG, H.Y., DU, Q., GRAHN, M., NORSTEDT, G., WAHLESTEDT, C., and LIANG, Z. (2008). Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res. 36, e53.
24. DE FOUGEROLLES, A., VORNLOCHER, H.P., MARAGANORE, J., and LIEBERMAN, J. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453.
25. DEVINCENZO, J., CEHELSKY, J.E., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V., VAN VLIET, A., VAISHNAW, A.K., and MEYERS, R. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77, 225-231.
26. DIEBOLD, S.S., KAISHO, T., HEMMI, H., AKIRA, S., and REIS E SOUSA, C. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531.
27. DOENCH, J.G., PETERSEN, C.P., and SHARP, P.A. (2003). siRNAs can function as miRNAs. Genes Dev. 17, 438-442.
28. DOENCH, J.G., and SHARP, P.A. (2004). Specificity of microRNA target selection in translational repression. Genes Dev. 18, 504-511.
29. DORE-SAVARD, L., ROUSSY, G., DANSEREAU, M.A., COLLINGWOOD, M.A., LENNOX, K.A., ROSE, S.D., BEAUDET, N., BEHLKE, M.A., and SARRET, P. (2008). Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol. Ther. 16, 1331-1339.
30. DOWLER, T., BERGERON, D., TEDESCHI, A.L., PAQUET, L., FERRARI, N., and DAMHA, M.J. (2006). Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res. 34, 1669-1675.
31. DU, Q., THONBERG, H., WANG, J., WAHLESTEDT, C., and LIANG, Z. (2005). A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33, 1671-1677.
32. EBERLE, F., GIESSLER, K., DECK, C., HEEG, K., PETER, M., RICHERT, C., and DALPKE, A.H. (2008). Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol 180, 3229-3237.
33. EDER, P.S., DEVINE, R.J., DAGLE, J.M., and WALDER, J.A. (1991). Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1, 141-151.
34. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
35. ELMEN, J., LINDOW, M., SCHUTZ, S., LAWRENCE, M., PETRI, A., OBAD, S., LINDHOLM, M., HEDTJARN, M., HANSEN, H.F., BERGER, U., GULLANS, S., KEARNEY, P., SARNOW, P., STRAARUP, E.M., and KAUPPINEN, S. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899.
36. ELMEN, J., THONBERG, H., LJUNGBERG, K., FRIEDEN, M., WESTERGAARD, M., XU, Y., WAHREN, B., LIANG, Z., ORUM, H., KOCH, T., and WAHLESTEDT, C. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33, 439-447.
37. FILIPOWICZ, W., BHATTACHARYYA, S.N., and SONENBERG, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114.
38. FILIPOWICZ, W., JASKIEWICZ, L., KOLB, F.A., and PILLAI, R.S. (2005). Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 15, 331-341.
39. FLUITER, K., TEN ASBROEK, A.L., DE WISSEL, M.B., JAKOBS, M.E., WISSENBACH, M., OLSSON, H., OLSEN, O., OERUM, H., and BAAS, F. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31, 953-962.
40. FRANK-KAMENETSKY, M., GREFHORST, A., ANDERSON, N.N., RACIE, T.S., BRAMLAGE, B., AKINC, A., BUTLER, D., CHARISSE, K., DORKIN, R., FAN, Y., GAMBA-VITALO, C., HADWIGER, P., JAYARAMAN, M., JOHN, M., JAYAPRAKASH, K.N., MAIER, M., NECHEV, L., RAJEEV, K.G., READ, T., ROHL, I., SOUTSCHEK, J., TAN, P., WONG, J., WANG, G., ZIMMERMANN, T., DE FOUGEROLLES, A., VORNLOCHER, H.P., LANGER, R., ANDERSON, D.G., MANOHARAN, M., KOTELIANSKY, V., HORTON, J.D., and FITZGERALD, K. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 105, 11915-11920.
41. GANTIER, M.P., TONG, S., BEHLKE, M.A., XU, D., PHIPPS, S., FOSTER, P.S., and WILLIAMS, B.R. (2008). TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol. 180, 2117-2124.
42. GRAESSMANN, M., MICHAELS, G., BERG, B., and GRAESSMANN, A. (1991). Inhibition of SV40 gene expression by microinjected small antisense RNA and DNA molecules. Nucleic Acids Res. 19, 53-58.
43. GRAGOUDAS, E.S., ADAMIS, A.P., CUNNINGHAM, E.T., JR., FEINSOD, M., and GUYER, D.R. (2004). Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816.
44. GREWAL, S.I., and ELGIN, S.C. (2007). Transcription and RNA interference in the formation of heterochromatin. Nature 447, 399-406.
45. GRILLONE, L.R., and LANZ, R. (2001). Fomivirsen. Drugs Today (Barc) 37, 245-255.
46. GRUNWELLER, A., WYSZKO, E., BIEBER, B., JAHNEL, R., ERDMANN, V.A., and KURRECK, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193.
47. HALL, A.H., WAN, J., SHAUGHNESSY, E.E., RAMSAY SHAW, B., and ALEXANDER, K.A. (2004). RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 32, 5991-6000.
48. HALL, A.H., WAN, J., SPESOCK, A., SERGUEEVA, Z., SHAW, B.R., and ALEXANDER, K.A. (2006). High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res. 34, 2773-2781.
49. HANNON, G.J., and ROSSI, J.J. (2004). Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378.
50. HARBORTH, J., ELBASHIR, S.M., VANDENBURGH, K., MANNINGA, H., SCARINGE, S.A., WEBER, K., and TUSCHL, T. (2003). Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83-105.
51. HAUPENTHAL, J., BAEHR, C., KIERMAYER, S., ZEUZEM, S., and PIIPER, A. (2006). Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem. Pharmacol. 71, 702-710.
52. HAUPENTHAL, J., BAEHR, C., ZEUZEM, S., and PIIPER, A. (2007). RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. Int. J. Cancer.
53. HE, L., and HANNON, G.J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531.
54. HEIDEL, J.D., HU, S., LIU, X.F., TRICHE, T.J., and DAVIS, M.E. (2004). Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol. 22, 1579-1582.
55. HEIDEL, J.D., LIU, J.Y., YEN, Y., ZHOU, B., HEALE, B.S., ROSSI, J.J., BARTLETT, D.W., and DAVIS, M.E. (2007a). Potent siRNA inhibitors of ribonucleotide reductase subunit rrm2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res. 13, 2207-2215.
56. HEIDEL, J.D., YU, Z., LIU, J.Y., RELE, S.M., LIANG, Y., ZEIDAN, R.K., KORNBRUST, D.J., and DAVIS, M.E. (2007b). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715-5721.
57. HEIL, F., HEMMI, H., HOCHREIN, H., AMPENBERGER, F., KIRSCHNING, C., AKIRA, S., LIPFORD, G., WAGNER, H., and BAUER, S. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526-1529.
58. HICKERSON, R.P., SMITH, F.J., REEVES, R.E., CONTAG, C.H., LEAKE, D., LEACHMAN, S.A., MILSTONE, L.M., MCLEAN, W.H., and KASPAR, R.L. (2008). Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J. Invest. Dermatol. 128, 594-605.
59. HOGREFE, R.I., LEBEDEV, A.V., ZON, G., PIROLLO, K.F., RAIT, A., ZHOU, Q., YU, W., and CHANG, E.H. (2006). Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25, 889-907.
60. HORNUNG, V., ELLEGAST, J., KIM, S., BRZOZKA, K., JUNG, A., KATO, H., POECK, H., AKIRA, S., CONZELMANN, K.K., SCHLEE, M., ENDRES, S., and HARTMANN, G. (2006). 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994-997.
61. HORNUNG, V., GUENTHNER-BILLER, M., BOURQUIN, C., ABLASSER, A., SCHLEE, M., UEMATSU, S., NORONHA, A., MANOHARAN, M., AKIRA, S., DE FOUGEROLLES, A., ENDRES, S., and HARTMANN, G. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270.
62. HUTVAGNER, G., and SIMARD, M.J. (2008). Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell. Biol. 9, 22-32.
63. JABS, D.A., and GRIFFITHS, P.D. (2002). Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. 133, 552-556.
64. JACKSON, A.L., BARTZ, S.R., SCHELTER, J., KOBAYASHI, S.V., BURCHARD, J., MAO, M., LI, B., CAVET, G., and LINSLEY, P.S. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637.
65. JACKSON, A.L., BURCHARD, J., LEAKE, D., REYNOLDS, A., SCHELTER, J., GUO, J., JOHNSON, J.M., LIM, L., KARPILOW, J., NICHOLS, K., MARSHALL, W., KHVOROVA, A., and LINSLEY, P.S. (2006a). Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205.
66. JACKSON, A.L., BURCHARD, J., SCHELTER, J., CHAU, B.N., CLEARY, M., LIM, L., and LINSLEY, P.S. (2006b). Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187.
67. JASON, T.L., KOROPATNICK, J., and BERG, R.W. (2004). Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201, 66-83.
68. JUDGE, A.D., BOLA, G., LEE, A.C., and MACLACHLAN, I. (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505.
69. JUDGE, A.D., SOOD, V., SHAW, J.R., FANG, D., MCCLINTOCK, K., and MACLACHLAN, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462.
70. JULIANO, R., ALAM, M.R., DIXIT, V., and KANG, H. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 4158-4171.
71. JULIANO, R.L. (2005). Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr. Opin. Mol. Ther. 7, 132-136.
72. KARIKO, K., BUCKSTEIN, M., NI, H., and WEISSMAN, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175.
73. KATO, H., TAKEUCHI, O., SATO, S., YONEYAMA, M., YAMAMOTO, M., MATSUI, K., UEMATSU, S., JUNG, A., KAWAI, T., ISHII, K.J., YAMAGUCHI, O., OTSU, K., TSUJIMURA, T., KOH, C.S., REIS E SOUSA, C., MATSUURA, Y., FUJITA, T., and AKIRA, S. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105.
74. KENNEDY, S., WANG, D., and RUVKUN, G. (2004). A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 427, 645-649.
75. KIM, D.H., BEHLKE, M.A., ROSE, S.D., CHANG, M.S., CHOI, S., and ROSSI, J.J. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226.
76. KIM, D.H., LONGO, M., HAN, Y., LUNDBERG, P., CANTIN, E., and ROSSI, J.J. (2004). Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321-325.
77. KIM, D.H., and ROSSI, J.J. (2007). Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184.
78. KIM, V.N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell. Biol. 6, 376-385.
79. KLEINMAN, M.E., YAMADA, K., TAKEDA, A., CHANDRASEKARAN, V., NOZAKI, M., BAFFI, J.Z., ALBUQUERQUE, R.J., YAMASAKI, S., ITAYA, M., PAN, Y., APPUKUTTAN, B., GIBBS, D., YANG, Z., KARIKO, K., AMBATI, B.K., WILGUS, T.A., DIPIETRO, L.A., SAKURAI, E., ZHANG, K., SMITH, J.R., TAYLOR, E.W., and AMBATI, J. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597.
80. KOLDEHOFF, M., STECKEL, N.K., BEELEN, D.W., and ELMAAGACLI, A.H. (2007). Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7, 47-55.
81. KRAYNACK, B.A., and BAKER, B.F. (2006). Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA 12, 163-176.
82. KRIEG, A.M., HARTMANN, G., and YI, A.K. (2000). Mechanism of action of CpG DNA. Curr. Top. Microbiol. Immunol. 247, 1-21.
83. KRIEG, A.M., and STEIN, C.A. (1995). Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5, 241.
84. KRIEG, A.M., YI, A.K., and HARTMANN, G. (1999). Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol. Ther. 84, 113-120.
85. KUBO, T., ZHELEV, Z., OHBA, H., and BAKALOVA, R. (2007). Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. Oligonucleotides 17, 445-464.
86. KUBO, T., ZHELEV, Z., OHBA, H., and BAKALOVA, R. (2008). Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect. Biochem. Biophys. Res. Commun. 365, 54-61.
87. LAYZER, J.M., MCCAFFREY, A.P., TANNER, A.K., HUANG, Z., KAY, M.A., and SULLENGER, B.A. (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771.
88. LEACHMAN, S.A., HICKERSON, R.P., HULL, P.R., SMITH, F.J., MILSTONE, L.M., LANE, E.B., BALE, S.J., ROOP, D.R., MCLEAN, W.H., and KASPAR, R.L. (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J. Dermatol. Sci. 51, 151-157.
89. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
90. LI, Z.Y., MAO, H., KALLICK, D.A., and GORENSTEIN, D.G. (2005). The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem. Biophys. Res. Commun. 329, 1026-1030.
91. LIM, L.P., LAU, N.C., GARRETT-ENGELE, P., GRIMSON, A., SCHELTER, J.M., CASTLE, J., BARTEL, D.P., LINSLEY, P.S., and JOHNSON, J.M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769-773.
92. LIN, X., RUAN, X., ANDERSON, M.G., MCDOWELL, J.A., KROEGER, P.E., FESIK, S.W., and SHEN, Y. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33, 4527-4535.
93. LORENZ, C., HADWIGER, P., JOHN, M., VORNLOCHER, H.P., and UNVERZAGT, C. (2004). Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975-4977.
94. MA, Z., LI, J., HE, F., WILSON, A., PITT, B., and LI, S. (2005). Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755-759.
95. MANOHARAN, M. (2002). Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12, 103-128.
96. MARQUES, J.T., DEVOSSE, T., WANG, D., ZAMANIANDARYOUSH, M., SERBINOWSKI, P., HARTMANN, R., FUJITA, T., BEHLKE, M.A., and WILLIAMS, B.R. (2006). A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 24, 559-565.
97. MARQUES, J.T., and WILLIAMS, B.R. (2005). Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23, 1399-1405.
98. MATTEUCCI, M. (1997). Oligonucleotide analogues: an overview. Ciba Found. Symp. 209, 5-14; discussion 14-18.
99. MEISTER, G., and TUSCHL, T. (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349.
100. MELLO, C.C., and CONTE, D., JR. (2004). Revealing the world of RNA interference. Nature 431, 338-342.
101. MELTON, D.A. (1985). Injected anti-sense RNAs specifically block messenger RNA translation in vivo. Proc. Natl. Acad. Sci. U.S.A 82, 144-148.
102. MINKS, M.A., WEST, D.K., BENVIN, S., and BAGLIONI, C. (1979). Structural requirements of double-stranded RNA for the activation of 2′,5′- oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J. Biol. Chem. 254, 10180-10183.
103. MOOK, O.R., BAAS, F., DE WISSEL, M.B., and FLUITER, K. (2007). Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 6, 833-843.
104. MORRISSEY, D.V., BLANCHARD, K., SHAW, L., JENSEN, K., LOCKRIDGE, J.A., DICKINSON, B., MCSWIGGEN, J.A., VARGEESE, C., BOWMAN, K., SHAFFER, C.S., POLISKY, B.A., and ZINNEN, S. (2005a). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41, 1349-1356.
105. MORRISSEY, D.V., LOCKRIDGE, J.A., SHAW, L., BLANCHARD, K., JENSEN, K., BREEN, W., HARTSOUGH, K., MACHEMER, L., RADKA, S., JADHAV, V., VAISH, N., ZINNEN, S., VARGEESE, C., BOWMAN, K., SHAFFER, C.S., JEFFS, L.B., JUDGE, A., MACLACHLAN, I., and POLISKY, B. (2005b). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007.
106. MUHONEN, P., TENNILA, T., AZHAYEVA, E., PARTHASARATHY, R.N., JANCKILA, A.J., VAANANEN, H.K., AZHAYEV, A., and LAITALA-LEINONEN, T. (2007). RNA interference tolerates 2′-fluoro modifications at the Argonaute2 cleavage site. Chem. Biodivers 4, 858-873.
107. NALLAGATLA, S.R., and BEVILACQUA, P.C. (2008). Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14, 1201-1213.
108. NISHINA, K., UNNO, T., UNO, Y., KUBODERA, T., KANOUCHI, T., MIZUSAWA, H., and YOKOTA, T. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734-740.
109. NOVOBRANTSEVA, T.I., AKINC, A., BORODOVSKY, A., and DE FOUGEROLLES, A. (2008). Delivering silence: advancements in developing siRNA therapeutics. Curr. Opin. Drug Discov. Devel. 11, 217-224.
110. OMI, K., TOKUNAGA, K., and HOHJOH, H. (2004). Long-lasting RNAi activity in mammalian neurons. FEBS Lett. 558, 89-95.
111. PEEK, A.S., and BEHLKE, M.A. (2007). Design of active small interfering RNAs. Curr. Opin. Mol. Ther. 9, 110-118.
112. PEI, Y., and TUSCHL, T. (2006). On the art of identifying effective and specific siRNAs. Nat. Methods 3, 670-676.
113. PERSENGIEV, S.P., ZHU, X., and GREEN, M.R. (2004). Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18.
114. PICHLMAIR, A., SCHULZ, O., TAN, C.P., NASLUND, T.I., LILJESTROM, P., WEBER, F., and REIS E SOUSA, C. (2006). RIGI-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997-1001.
115. PIROLLO, K.F., RAIT, A., ZHOU, Q., HWANG, S.H., DAGATA, J.A., ZON, G., HOGREFE, R.I., PALCHIK, G., and CHANG, E.H. (2007). Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67, 2938-2943.
116. PRAKASH, T.P., ALLERSON, C.R., DANDE, P., VICKERS, T.A., SIOUFI, N., JARRES, R., BAKER, B.F., SWAYZE, E.E., GRIFFEY, R.H., and BHAT, B. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48, 4247-4253.
117. RANA, T.M. (2007). Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell. Biol. 8, 23-36.
118. REYNOLDS, A., ANDERSON, E.M., VERMEULEN, A., FEDOROV, Y., ROBINSON, K., LEAKE, D., KARPILOW, J., MARSHALL, W.S., and KHVOROVA, A. (2006). Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 12, 988-993.
119. RICHARDSON, F.C., TENNANT, B.C., MEYER, D.J., RICHARDSON, K.A., MANN, P.C., MCGINTY, G.R., WOLF, J.L., ZACK, P.M., and BENDELE, R.A. (1999). An evaluation of the toxicities of 2′-fluorouridine and 2′- fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol. Pathol. 27, 607-617.
120. RICHARDSON, F.C., ZHANG, C., LEHRMAN, S.R., KOC, H., SWENBERG, J.A., RICHARDSON, K.A., and BENDELE, R.A. (2002). Quantification of 2′-fluoro-2′-deoxyuridine and 2′-fluoro-2′-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chem. Res. Toxicol. 15, 922-926.
121. ROBBINS, M., JUDGE, A., LIANG, L., MCCLINTOCK, K., YAWORSKI, E., and MACLACHLAN, I. (2007). 2′-O-methyl-modified RNAs Act as TLR7 Antagonists. Mol. Ther. 15, 1663-1669.
122. ROBBINS, M.A., LI, M., LEUNG, I., LI, H., BOYER, D.V., SONG, Y., BEHLKE, M.A., and ROSSI, J.J. (2006). Stable expression of shRNAs in human CD34(+) progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat. Biotechnol. 24, 566-571.
123. ROSE, S.D., KIM, D.H., AMARZGUIOUI, M., HEIDEL, J.D., COLLINGWOOD, M.A., DAVIS, M.E., ROSSI, J.J., and BEHLKE, M.A. (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 33, 4140-4156.
124. SAITO, T., OWEN, D.M., JIANG, F., MARCOTRIGIANO, J., and GALE, M., JR. (2008). Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523-527.
125. SANTEL, A., ALEKU, M., KEIL, O., ENDRUSCHAT, J., ESCHE, V., DURIEUX, B., LOFFLER, K., FECHTNER, M., ROHL, T., FISCH, G., DAMES, S., ARNOLD, W., GIESE, K., KLIPPEL, A., and KAUFMANN, J. (2006a). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13, 1360-1370.
126. SANTEL, A., ALEKU, M., KEIL, O., ENDRUSCHAT, J., ESCHE, V., FISCH, G., DAMES, S., LOFFLER, K., FECHTNER, M., ARNOLD, W., GIESE, K., KLIPPEL, A., and KAUFMANN, J. (2006b). A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13, 1222-1234.
127. SAXENA, S., JONSSON, Z.O., and DUTTA, A. (2003). Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 278, 44312-44319.
128. SCACHERI, P.C., ROZENBLATT-ROSEN, O., CAPLEN, N.J., WOLFSBERG, T.G., UMAYAM, L., LEE, J.C., HUGHES, C.M., SHANMUGAM, K.S., BHATTACHARJEE, A., MEYERSON, M., and COLLINS, F.S. (2004). Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101, 1892-1897.
129. SCHLEE, M., HORNUNG, V., and HARTMANN, G. (2006). siRNA and isRNA: two edges of one sword. Mol. Ther. 14, 463-470.
130. SCHWARZ, D.S., DING, H., KENNINGTON, L., MOORE, J.T., SCHELTER, J., BURCHARD, J., LINSLEY, P.S., ARONIN, N., XU, Z., and ZAMORE, P.D. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2.
131. SHAH, S., and FRIEDMAN, S.H. (2007). Tolerance of RNA interference toward modifications of the 5′ antisense phosphate of small interfering RNA. Oligonucleotides 17, 35-43.
132. SHEN, J., SAMUL, R., SILVA, R.L., AKIYAMA, H., LIU, H., SAISHIN, Y., HACKETT, S.F., ZINNEN, S., KOSSEN, K., FOSNAUGH, K., VARGEESE, C., GOMEZ, A., BOUHANA, K., AITCHISON, R., PAVCO, P., and CAMPOCHIARO, P.A. (2006). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13, 225-234.
133. SIOUD, M. (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090.
134. SIOUD, M. (2006). Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur. J. Immunol. 36, 1222-1230.
135. SIOUD, M., and SORENSEN, D.R. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220-1225.
136. SONG, E., LEE, S.K., DYKXHOORN, D.M., NOVINA, C., ZHANG, D., CRAWFORD, K., CERNY, J., SHARP, P.A., LIEBERMAN, J., MANJUNATH, N., and SHANKAR, P. (2003). Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77, 7174-7181.
137. SONTHEIMER, E.J. (2005). Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell. Biol. 6, 127-138.
138. SOUTSCHEK, J., AKINC, A., BRAMLAGE, B., CHARISSE, K., CONSTIEN, R., DONOGHUE, M., ELBASHIR, S., GEICK, A., HADWIGER, P., HARBORTH, J., JOHN, M., KESAVAN, V., LAVINE, G., PANDEY, R.K., RACIE, T., RAJEEV, K.G., ROHL, I., TOUDJARSKA, I., WANG, G., WUSCHKO, S., BUMCROT, D., KOTELIANSKY, V., LIMMER, S., MANOHARAN, M., and VORNLOCHER, H.P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178.
139. STARK, G.R., KERR, I.M., WILLIAMS, B.R., SILVERMAN, R.H., and SCHREIBER, R.D. (1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
140. STEPHENSON, M.L., and ZAMECNIK, P.C. (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 285-288.
141. SWAYZE, E.E., SIWKOWSKI, A.M., WANCEWICZ, E.V., MIGAWA, M.T., WYRZYKIEWICZ, T.K., HUNG, G., MONIA, B.P., and BENNETT, C.F. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700.
142. TOSI, M.F. (2005). Innate immune responses to infection. J. Allergy Clin. Immunol. 116, 241-249; quiz 250.
143. TURNER, J.J., JONES, S.W., MOSCHOS, S.A., LINDSAY, M.A., and GAIT, M.J. (2007). MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biosyst. 3, 43-50.
144. UI-TEI, K., NAITO, Y., ZENNO, S., NISHI, K., YAMATO, K., TAKAHASHI, F., JUNI, A., and SAIGO, K. (2008). Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 36, 2136-2151.
145. VIEL, T., BOISGARD, R., KUHNAST, B., JEGO, B., SIQUIER-PERNET, K., HINNEN, F., DOLLE, F., and TAVITIAN, B. (2008). Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). Oligonucleotides 18, 201-212.
146. WANG, H., GHOSH, A., BAIGUDE, H., YANG, C.S., QIU, L., XIA, X., ZHOU, H., RANA, T.M., and XU, Z. (2008). Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J. Biol. Chem. 283, 15845-15852.
147. WEITZER, S., and MARTINEZ, J. (2007). The human RNA kinase hClp1 is active on 3′ transfer RNA exons and short interfering RNAs. Nature 447, 222-226.
148. WHELAN, J. (2005). First clinical data on RNAi. Drug Discov. Today 10, 1014-1015.
149. WOLFRUM, C., SHI, S., JAYAPRAKASH, K.N., JAYARAMAN, M., WANG, G., PANDEY, R.K., RAJEEV, K.G., NAKAYAMA, T., CHARRISE, K., NDUNGO, E.M., ZIMMERMANN, T., KOTELIANSKY, V., MANOHARAN, M., and STOFFEL, M. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157.
150. YEKTA, S., SHIH, I.H., and BARTEL, D.P. (2004). MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594-596.
151. YONEYAMA, M., KIKUCHI, M., NATSUKAWA, T., SHINOBU, N., IMAIZUMI, T., MIYAGISHI, M., TAIRA, K., AKIRA, S., and FUJITA, T. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730-737.
152. ZAMANIAN-DARYOUSH, M., MARQUES, J.T., GANTIER, M.P., BEHLKE, M.A., JOHN, M., RAYMAN, P., FINKE, J., and WILLIAMS, B.R. (2008). Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon Cytokine Res. 28, 221-233.
153. ZAMECNIK, P.C., and STEPHENSON, M.L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 75, 280-284.
154. ZOU, Y., TILLER, P., CHEN, I.W., BEVERLY, M., and HOCHMAN, J. (2008). Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 22, 1871-1881.